MaxCyte, Inc. APEIRON Biologics Clinical and Commercial License (3179S)
July 08 2020 - 2:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 3179S
MaxCyte, Inc.
08 July 2020
FOR IMMEDIATE RELEASE
APEIRON Biologics and MaxCyte Enter into Clinical and
Commercial Licensing Agreement for APN401
APEIRON to utilize MaxCyte's ExPERT(R) platform for siRNA-based
cell therapy APN401 targeting solid tumors and secures
manufacturing for upcoming clinical trials
VIENNA , AUSTRIA and GAITHERSBURG, MD, 8 July 2020 - APEIRON
Biologics AG ("APEIRON"), a private biotechnology company
specializing in the discovery, development and commercialization of
novel immunotherapies for cancer and respiratory diseases, and
MaxCyte, Inc., (LSE: MXCT, MXCL), a global cell-based therapies and
life sciences company, today announces the signing of a clinical
and commercial licensing agreement.
APEIRON Biologics will obtain non-exclusive clinical and
commercial rights to use MaxCyte's Flow Electroporation(R)
technology and ExPERT(TM) platform for the advancement of APN401, a
siRNA-based cell therapy currently in clinical development for
various solid tumors . In return, MaxCyte will receive undisclosed
development and approval milestones and sales-based payments in
addition to other licensing fees.
"Securing access to MaxCyte's ExPERT platform and unique
electroporation technology is a crucial next step in the clinical
advancement of our lead checkpoint inhibition Cbl-b candidate
APN401," said Peter Llewellyn-Davies, CEO of APEIRON Biologics.
Doug Doerfler, President & CEO of MaxCyte, said: "We are
proud to support APEIRON in the development of a siRNA-based
treatment that could help patients facing cancers with various
forms of tumors. This agreement represents an important achievement
for MaxCyte, and highlights the value of our next-generation
technology platform to companies across the globe seeking to unlock
the potential of their engineered cell therapy programs."
MaxCyte's ExPERT instrument portfolio represents the next
generation of leading, clinically validated, electroporation
technology for complex and scalable cell engineering. By delivering
high transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT platform delivers the high-end
performance essential to enable the next wave of biological and
cellular therapeutics.
About APEIRON Biologics AG
APEIRON Biologics AG is a European private biotechnology company
based in Vienna that specializes in the discovery, development and
commercialization of novel immunotherapies for cancer and
respiratory diseases. APEIRON's approved cancer drug Qarziba(R) is
being marketed by EUSA Pharma Ltd.. With APN01, APEIRON is
conducting a clinical trial in Europe for the treatment of
COVID-19, for which market approval is being sought. APEIRON's
APN401 clinical program is a "first-in-class" autologous cell
therapy for strengthening immunoreactivity via the intra-cellular
master checkpoint Cbl-b. APEIRON's products and technologies are
based on a strong patent portfolio and partnerships with leading
pharmaceutical companies and academic institutions.
For more information, visit www.apeiron-biologics.com
About MaxCyte
MaxCyte, the clinical-stage global cell-based therapies and life
sciences company, uses its proprietary next-generation cell and
gene therapies to revolutionise medical treatments and ultimately
save lives. The Company's premier cell engineering enabling
technology is currently being deployed by leading drug developers
worldwide, including all of the top ten global biopharmaceutical
companies. MaxCyte licences have been granted to more than 100 cell
therapy programmes, with more than 70 licensed for clinical use,
and the Company has now entered into eleven clinical/commercial
license partnerships with leading cell therapy and gene editing
developers. MaxCyte was founded in 1998, is listed on the London
Stock Exchange (AIM:MXCT, MXCL) and is headquartered in
Gaithersburg , Maryland, US. For more information, visit
www.maxcyte.com .
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 (MAR).
APEIRON Contacts:
APEIRON Biologics AG
Peter Llewellyn-Davies, CEO
Email: investors@apeiron-biologics.com
Media and Investor Relations +49 89 210 228 0
MC Services AG
Julia Hofmann
Email: apeiron@mc-services.eu
MaxCyte Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301-944-1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-com
Mary-Jane Elliott
Chris Welsh
--------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRKKOBBFBKDPOK
(END) Dow Jones Newswires
July 08, 2020 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024